Adenostemmoic acid B is primarily studied for its potential anti-inflammatory and immunomodulatory properties. It has shown inhibitory effects on pro-inflammatory cytokines, making it a candidate for research in autoimmune and chronic inflammatory conditions. The compound also exhibits moderate cytotoxic activity against certain cancer cell lines, suggesting possible utility in oncology drug development. Due to its natural origin and structural complexity, it serves as a lead compound for synthetic analogs aimed at enhancing bioavailability and therapeutic efficacy. Current applications remain in the preclinical research phase, focusing on pharmacological profiling and mechanism of action studies.